The DMTN Knockout NCI-H1299 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population in which the DMTN gene has been disrupted to create a loss-of-function model for dematin. Derived from the human NCI-H1299 non-small cell lung cancer cell line, these cells lack functional dematin expression, providing a robust platform for studying actin cytoskeleton biology in a cancer-relevant context. The polyclonal nature of the population ensures a heterogeneous allelic background, minimizing clonal artifacts and enabling broad assessment of DMTN-dependent cellular phenotypes.
NCI-H1299 is a widely used human lung adenocarcinoma cell line, originally established from a lymph node metastasis of a 43-year-old male patient. These cells are p53-deficient, a hallmark of aggressive tumors, and display characteristics of epithelial origin with mesenchymal traits. They are frequently employed in cancer research for investigating signal transduction, drug responses, and mechanisms underlying metastatic progression. The p53-null background also eliminates confounding p53-mediated effects, allowing focused analysis of cytoskeletal regulation.
DMTN encodes dematin, an actin-binding and crosslinking protein that stabilizes actin filaments and maintains cortical cytoskeletal integrity. Dematin is phosphorylated and regulated by the Rho family GTPases RhoA and Rac1, acting through downstream kinases ROCK and LIMK. It directly interacts with spectrin, adducin, and protein 4.1 to organize the membrane-associated actin network, and it functions within the RhoA/ROCK/LIMK/cofilin pathway to modulate actin polymerization. Knockout of DMTN disrupts these interactions, leading to disorganized actin filament architecture, compromised cell adhesion, and altered cell motility and mechanical properties.
In the NCI-H1299 lung adenocarcinoma model, loss of dematin offers a unique opportunity to dissect the role of actin-crosslinking proteins in cancer cell behavior. Disrupted actin dynamics may influence tumor cell migration, invasion, and response to the microenvironment, processes that are critical for metastatic dissemination. The interplay between dematin and Rho GTPase signaling is of particular interest in understanding how cytoskeletal reorganization drives cancer progression. Additionally, this model bridges the gap between erythrocyte biology??where DMTN mutations cause hereditary spherocytosis??and the emerging non-erythroid functions of dematin in solid tumors.
These polyclonal knockout cells are ideally suited for a range of assays, including immunofluorescence staining of F-actin to visualize cytoskeletal changes, scratch wound healing and Transwell invasion assays to quantify cell motility and invasiveness, and Rho GTPase activity pull-down assays to evaluate signaling pathway activation. Western blotting for dematin and actin confirms gene disruption, while drug screening studies can identify cytoskeleton-modulating compounds. The DMTN knockout platform thus supports both fundamental mechanistic investigations and translational applications in cancer biology. For further information, please contact Ascent Research.
